AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
[More]
Arbor Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved its New Drug Application for Nymalize (nimodipine) oral solution.
[More]
Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.
[More]
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers.
[More]
Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.
[More]
Migraine headaches are a major cause of ill health and a reduced quality of life. Some individuals suffer from a frequent and severe migraine problem which means that they require regular medication to try and prevent them.
[More]
L-carnitine significantly improves cardiac health in patients after a heart attack, say a multicenter team of investigators in a study published today in Mayo Clinic Proceedings.
[More]
High blood pressure in the kidneys of people with apple-shaped bodies may be responsible for their increased risk of developing kidney disease later in life, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.
[More]
A UCLA study shows that heart failure medications recommended by national guidelines are highly cost effective in saving lives and may also provide savings to the health care system.
[More]
The American Physiological Society is one of six scientific societies sponsoring the meeting Experimental Biology 2013, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, in Boston, Mass.
[More]
A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.
[More]
Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status, according to a study published online by JAMA.
[More]
African-American women who survive breast cancer are more likely to develop heart failure than other women who have beaten the disease, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session.
[More]
The importance of left ventricular diastolic function improvement in patients with heart failure with preserved ejection fraction has been questioned, after researchers found that treatment with spironolactone resulted in some functional improvements but failed to impact on patients’ exercise capacity.
[More]
A senior staff scientist and his team at Henry Ford Hospital have been awarded a five-year, $12.4 million grant by the National Institutes of Health for their research into the damaging effects of high blood pressure on various organs in the body.
[More]
Steroid therapy is associated with a considerable reduction in all-cause mortality and new-onset and progressive cardiomyopathy in patients with the debilitating X-linked disease Duchenne muscular dystrophy.
[More]
Six months of treatment with the angiotensin-converting enzyme inhibitor ramipril produces notable improvements in the walking ability of patients with peripheral artery disease and intermittent claudication, shows a large randomized trial.
[More]
Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA.
[More]
Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.
[More]